Mirvaso (brimonidine)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
July 2016
CONTRAINDICATIONS
MIRVASO topical gel is contraindicated in patients who have experienced a hypersensitivity reaction to...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology